286 related articles for article (PubMed ID: 16686924)
21. EU--US experts urge stiffer rules for biotech foods.
Fox JL
Nat Biotechnol; 2001 Feb; 19(2):106-7. PubMed ID: 11175716
[No Abstract] [Full Text] [Related]
22. Opposition in search of a rationale: the case for Food and Drug Administration regulation.
Myers ML
Tob Control; 2004 Dec; 13(4):441-3. PubMed ID: 15564634
[No Abstract] [Full Text] [Related]
23. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?
Faden LB; Milne CP
Food Drug Law J; 2008; 63(3):683-700. PubMed ID: 19031668
[No Abstract] [Full Text] [Related]
24. US FDA outreach to the regenerative medicine community: challenges and opportunities.
Whittlesey KJ; Witten C
Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
[TBL] [Abstract][Full Text] [Related]
25. Is the FDA regulating the practice of medicine?
Aicher RH
Aesthet Surg J; 2013 Mar; 33(3):452-5. PubMed ID: 23515389
[No Abstract] [Full Text] [Related]
26. FDA on transgenic animals--a dog's breakfast?
Miller HI
Nat Biotechnol; 2008 Feb; 26(2):159-60. PubMed ID: 18259164
[No Abstract] [Full Text] [Related]
27. European Medicines Agency, CAT Secretariat & US Food and Drug Administration.
Regen Med; 2011 Nov; 6(6 Suppl):90-6. PubMed ID: 21999268
[TBL] [Abstract][Full Text] [Related]
28. 8 keys to compliance for Medical Science Liaisons.
Werling K; Heinze G
Health Care Law Mon; 2007 Apr; ():3-6. PubMed ID: 17476734
[No Abstract] [Full Text] [Related]
29. Pros and cons of off-label promotion investigations and prosecutions.
Loucks MK
Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
[No Abstract] [Full Text] [Related]
30. Ignore FDA reform at your peril.
Fulton A
AHIP Cover; 2007; 48(4):8, 54. PubMed ID: 17713032
[No Abstract] [Full Text] [Related]
31. What can be learnt from the Japanese regulatory approach to tissue engineered products?
Brévignon-Dodin L; Livesey F
Regen Med; 2007 Nov; 2(6):967-71. PubMed ID: 18034634
[TBL] [Abstract][Full Text] [Related]
32. Mandatory recall authority: a sensible and minimalist approach to improving food safety.
Roberts MT
Food Drug Law J; 2004; 59(4):563-83. PubMed ID: 15875352
[No Abstract] [Full Text] [Related]
33. FDA has a change of heart.
Neil R
Mater Manag Health Care; 2006 May; 15(5):9. PubMed ID: 16761870
[No Abstract] [Full Text] [Related]
34. Expect more scrutiny of MDR compliance.
Kurlander SS
Adv Wound Care; 1997; 10(3):20. PubMed ID: 9306774
[No Abstract] [Full Text] [Related]
35. Post-marketing strategies for medicines.
Breckenridge A
Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
[No Abstract] [Full Text] [Related]
36. Regulation of dietary supplement advertising: current claims of interest to the Federal Trade Commission, Food and Drug Administration and National Advertising Division.
Villafranco JE; Lustigman AB
Food Drug Law J; 2007; 62(4):709-25. PubMed ID: 18557227
[No Abstract] [Full Text] [Related]
37. Progress on regulations for human-derived therapeutic products.
Cox M
Med Device Technol; 2003; 14(1):32-4. PubMed ID: 12974123
[TBL] [Abstract][Full Text] [Related]
38. EC-FDA mutual recognition agreement proves difficult.
Hodgson J
Nat Biotechnol; 1997 Feb; 15(2):119-20. PubMed ID: 9035127
[No Abstract] [Full Text] [Related]
39. Anticipating new consumer protection challenges in the food and drug marketplace.
Parnes LB
Food Drug Law J; 2008; 63(2):593-9. PubMed ID: 18561480
[No Abstract] [Full Text] [Related]
40. The European hospital exemption clause-new option for gene therapy?
Buchholz CJ; Sanzenbacher R; Schüle S
Hum Gene Ther; 2012 Jan; 23(1):7-12. PubMed ID: 22247961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
